News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Global Pharmatech Appoints Dr. Shijie Yang As Chairman And President Of Jilin Tian Yao Drug Safety Evaluation Co., Ltd.



10/19/2005 5:13:23 PM

JILIN, China, Oct. 18 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. , a company which combines R&D of botanical drug products, manufacturing, and sales and marketing for the Over-the-Counter (OTC) and prescription drug markets, announced today that Jilin Tian Yao Drug Safety Evaluation Co., Ltd. (JDE), a wholly owned subsidiary of Global Pharmatech, Inc. (GBLP), has recently appointed Dr. Shijie Yang as its Chairman and President. Dr. Yang is a well-respected and highly reputable scientist in the Chinese medical field. He is an expert in pre-clinical drug development and evaluation. Dr. Yang graduated in 1970 from Jilin Medical University, and obtained his Ph.D. degree in 1995 from Aichi Medical University, Japan. During the past ten years, he worked as a professor and then as the Chairman of Department of Pharmacology at Bethune Medical University. Prior to joining the company, he worked as the Dean of College of Basic Medical Sciences at Jilin University.

Dr. Yang is an expert advisor for the Chinese regulatory authority, the State Food and Drug Administration (SFDA). He also holds positions in various scientific associations and was editor of several pharmacology textbooks used by Chinese medical students. From 1996 to present, he has been supervising more than 50 graduate students, including 15 Ph.D. students. Dr. Yang has more than 60 publications and received several important scientific awards from the Chinese government, as well as from various scientific organizations.

Research focuses of Dr. Yang are cardiovascular pharmacology and molecular pharmacology. He has been using molecular biological technologies to discover drug candidates with potential activities for the treatment of arrhythmia, myocardial ischemia and apoptosis. His most recent research project is ''the pharmacological activities of Triterpenoid Saponis against ischemia in cerebral and myocardial tissues.''

Dr. Sun Xiaobo, President and CEO of Global Pharmatech, commented, ''We are very pleased to have Dr. Yang in our company. As a newly appointed Chairman and President, Dr. Yang will be able to bring many new clients and government-sponsored research projects into the company. Recruitment of Dr. Yang will significantly improve the image of GBLP in both domestic and international medical fields.''

About Global Pharmatech

Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine while utilizing modern facilities and advanced R&D technologies. Global Pharmatech offers a full range of ''start to finish'' biotech services, from R&D and testing, to manufacturing drugs in liquid and solid dose forms, to sales and marketing. Global Pharmatech utilizes unique extraction methods and innovative techniques that have been developed by its R&D team. Global Pharmatech's core business to date has been licensing its R&D patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution in China, Malaysia, Singapore and Indonesia.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please contact: Zhuojun Li, Investor Relations, Global Pharmatech, Inc. Tel: +1-905-787-8225 Fax: +1-905-787-9711 Email: zhuojunli@global-pharmatech.com

Global Pharmatech, Inc.

CONTACT: Zhuojun Li, Investor Relations of Global Pharmatech, Inc.,+1-905-787-8225, or fax, +1-905-787-9711, orzhuojunli@global-pharmatech.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES